Background
A.D.W. was admitted to the Colorado Mental Health Hospital in Pueblo after being found incompetent to proceed in a criminal case. His psychiatrist diagnosed an unspecified mood disorder marked by hallucinations, paranoia, delusions, agitation, impulsivity, and aggressive behavior toward staff.
After A.D.W. intermittently complied with medication and later threatened and swung at staff, the State sought authorization to administer Zyprexa, Thorazine, and Depakote without his consent, along with related laboratory monitoring. The district court granted the petition under People v. Medina.
The Court’s Holding
The Colorado Court of Appeals affirmed. Credited psychiatric testimony supported the finding that A.D.W. could not effectively participate in treatment decisions because he lacked insight into how his illness caused his symptoms and how the requested medications addressed them.
The court also upheld the finding that A.D.W.’s treatment need outweighed his asserted interest in refusing medication. He did not challenge the findings that medication was necessary to prevent likely long-term deterioration and serious harm to others in the hospital, and evidence showed his assaultive behavior had substantially improved while medicated.
Key Takeaways
- A patient may be unable to effectively participate in a treatment decision even if able to state coherent medication preferences.
- A treating physician’s credited testimony can alone support the Medina criteria for involuntary antipsychotic medication.
- Individualized findings stated in an oral ruling may supplement a shorter written order.
Why It Matters
The decision confirms that courts applying Medina may focus on whether a patient understands the relationship among mental illness, symptoms, and proposed treatment—not simply whether the patient can articulate objections. It also underscores the deference appellate courts give to trial courts’ credibility determinations in involuntary-medication proceedings.